Minying Li

Minying Li

Auto-generated profile, based on publicly available information

Minying Li

Department of Radiation Oncology, Zhongshan People's Hospital, Zhongshan, China

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2024 in Aging
Verified
Journal Article
Open access
PDF file
XYXinyu Yan
Xinyu Yan
PYPeixuan Yang
Peixuan Yang
YLYani Li
Yani Li
TLTing Liu
Ting Liu
YZYawen Zha
Yawen Zha
MLMinying Li
Minying Li
Mitochondrial DNA (mtDNA) copy number and telomere length (TL) are dynamic factors that have been linked to the aging process in organisms. However, the causal relationship between these variables remains uncertain. In this research, instrumental variables (IVs) related to mtDNA copy number and TL were obtained from publicly available genome-wide association studies (GWAS). Through bidirectional Mendelian randomization (MR) analysis, we examined the potential causal relationship between these factors. The forward analysis, with mtDNA copy number as the exposure and TL as the outcome, did not reveal a significant effect (B=-0.004, P>0.05). On the contrary, upon conducting a reverse analysis, it was found that there exists a positive causal relationship (B=0.054, P<0.05). Sensitivity analyses further confirmed the reliability of these results. The outcomes of this study indicate a one-way positive causal relationship, indicating that telomere shortening in the aging process may lead to a decrease in mtDNA copy number, providing new perspectives on their biological mechanisms.

6 April 2022 in Cancer Gene Therapy
Verified
Journal Article
Open access
PDF file
DLDeng-Ke Li
Deng-Ke Li
XCXing-Rui Chen
Xing-Rui Chen
LWLi-Na Wang
Li-Na Wang
JWJia-Hong Wang
Jia-Hong Wang
JLJi-Ke Li
Ji-Ke Li
KYKai-Tai Yao
Kai-Tai Yao
Increased vascular permeability facilitates metastasis. Cancer-secreted exosomes are emerging mediators of cancer-host crosstalk. Epstein-Barr virus (EBV), identified as the first human tumor-associated virus, plays a crucial role in metastatic tumors, especially in nasopharyngeal carcinoma (NPC). To date, whether and how exosomes from EBV-infected NPC cells affect vascular permeability remains unclear. Here, we show that exosomes from EBV-positive NPC cells, but not exosomes from EBV-negative NPC cells, destroy endothelial cell tight junction (TJ) proteins, which are natural barriers against metastasis, and promote endothelial-to-mesenchymal transition (EndMT) in endothelial cells. Proteomic analysis revealed that the level of HMGA2 protein was higher in exosomes derived from EBV-positive NPC cells compared with that in exosomes derived from EBV-negative NPC cells. Depletion of HMGA2 in exosomes derived from EBV-positive NPC cells attenuates endothelial cell dysfunction and tumor cell metastasis. In contrast, exosomes from HMGA2 overexpressing EBV-negative NPC cells promoted these processes. Furthermore, we showed that HMGA2 upregulates the expression of Snail, which contributes to TJ proteins reduction and EndMT in endothelial cells. Moreover, the level of HMGA2 in circulating exosomes is significantly higher in NPC patients with metastasis than in those without metastasis and healthy negative controls, and the level of HMGA2 in tumor cells is associated with TJ and EndMT protein expression in endothelial cells. Collectively, our findings suggest exosomal HMGA2 from EBV-positive NPC cells promotes tumor metastasis by targeting multiple endothelial TJ and promoting EndMT, which highlights secreted HMGA2 as a potential therapeutic target and a predictive marker for NPC metastasis.

6 February 2024 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
CYChen Yang
Chen Yang
RZRui Zeng
Rui Zeng
YZYawen Zha
Yawen Zha
YLYani Li
Yani Li
TWTing Wang
Ting Wang
JZJingjing Zhang
Jingjing Zhang
In patients with advanced lung adenocarcinoma (LADC) harboring the echinoderm microtubule-associated protein-like 4 (EML4) -anaplastic lymphoma kinase (ALK) rearrangement, targeted therapy typically demonstrates superior efficacy as an initial treatment compared to chemotherapy. Following resistance to ALK-tyrosine kinase inhibitors (TKIs), regimens incorporating platinum-based dual agents or combined with bevacizumab often show effectiveness. However, therapeutic alternatives become constrained after resistance develops to both TKIs and platinum-based therapies. Given that the majority of ALK-positive non-small cell lung carcinomas (NSCLC) are LADC, the benefits of TKIs for patients with ALK-positive lung squamous cell carcinoma (LSCC) and the optimal treatment strategy for these patients remain a subject of debate. In this case study, we report on a patient with advanced LSCC, in whom the EML4-ALK rearrangement was identified via ARMS-PCR (Amplification Refractory Mutation System-Polymerase Chain Reaction). The patient underwent oral treatment with crizotinib and alectinib, showing effectiveness in both first-line and second-line ALK-TKI therapies, albeit with limited progression-free survival (PFS). Subsequent resistance to second-generation TKI was followed by the detection of tumors in the left neck region via computed tomography (CT). Biopsy pathology revealed non-squamous cell carcinoma, and subsequent treatment with platinum-based double-drug therapy proved ineffective. Further analysis through next-generation sequencing (NGS) indicated ALK negativity but a high expression of programmed death-ligand 1 (PD-L1). Immunotherapy was then initiated, resulting in a PFS of over 29 months and clinical complete remission (cCR). This case underscores the potential benefit of ALK-TKIs in patients with ALK-positive LSCC. Resistance to second-generation TKIs may lead to ALK negativity and histological transformation, highlighting the necessity of repeated biopsies post-TKI resistance for informed treatment decision-making. As of November 2023, imaging studies continue to indicate cCR in the patient, with a survival time exceeding 47 months.

20 February 2025 in Medical Dosimetry
Verified
Journal Article
Open access
ZLZhen Li
Zhen Li
XYXin Yang
Xin Yang
HZHuaqu Zeng
Huaqu Zeng
JYJianrong Yu
Jianrong Yu
SZSiming Zheng
Siming Zheng
MLMinying Li
Minying Li
To assess the dosimetric characteristics of HyperArc (HA), noncoplanar VMAT (NC-plan), and coplanar VMAT (HL3arc) in hippocampal-sparing whole-brain radiotherapy (WBRT). Twenty patients undergoing WBRT at our Hospital from June 2021 to March 2023 were selected. The dose parameters of organs at risk (OARs) were evaluated for all three groups, including D100%, Dmax, and Dmean of hippocampus, Dmax to the lens, eyes, optic nerves, and chiasm, Dmean to the scalp and upper neck, and the dose volume parameters V5Gy, V10Gy, V15Gy, V20Gy for the upper neck. The D98%, V28.5Gy, D2%, HI, CI, GI for PTV, as well as planning time, and beam-on time. HA had the lowest hippocampal Dmax and Dmean. HA's scalp Dmean was lower than HL3arc (p = 0.007). HA's upper neck region Dmean and V5-20Gy(cm3) were significantly higher than NC-VMAT and HL3arc. For PTV, HA's D98 and V28.5Gy were higher than NC-VMAT and HL3arc (p < 0.05). HA exhibited a significant advantage in terms of HI, CI and GI. The average planning times were 84.67, 17.30, and 20.40 minutes. Among the three treatment approaches, HA demonstrated the lowest bilateral hippocampal doses, but it exhibited the highest average dose and low-dose volume in the upper neck region, with the longest planning optimization process.

8 May 2025 in Heliyon
Verified
Journal Article
Open access
TLTao Lin
Tao Lin
XTXusheng Tang
Xusheng Tang
WYWanli Yang
Wanli Yang
HYHainan Yang
Hainan Yang
ZZZhaoming Zhou
Zhaoming Zhou
LWLei Wen
Lei Wen
[This corrects the article DOI: 10.1016/j.heliyon.2024.e36532.].

1 August 2010
Verified
Journal Article
Closed access
MLMin-Ying Li
Min-Ying Li
FLFeng Lei
Feng Lei
WYWei You
Wei You
YTYu-Jing Tan
Yu-Jing Tan
XLXiao-Jun Lu
Xiao-Jun Lu
JZJi-Ren Zhang
Ji-Ren Zhang